Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

Leukemia Research

Volumn 29, Issue 1, 2005, Pages 53-57

  Nabhan, Chadi ^a   Rundhaugen, Lynn M ^b   Riley, Mary B ^b   Rademaker, Alfred ^b   Boehlke, Larry ^b   Jatoi, Mashal ^b   Tallman, Martin S ^b  

^a ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Gemtuzumab ozogamicin; Leukemia; Older adults

Indexed keywords

ANTIBIOTIC AGENT; CELECOXIB; DIPHENHYDRAMINE; GEMTUZUMAB OZOGAMICIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; KARYOTYPE; KIDNEY FAILURE; LEUKOPENIA; LIVER SINUSOID; LUNG TOXICITY; MAINTENANCE THERAPY; MALE; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; VEIN OCCLUSION; VOMITING; WEIGHT REDUCTION;

ACUTE DISEASE; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FEVER; HUMANS; IMMUNOCONJUGATES; LEUKEMIA, MYELOID; MALE; TREATMENT OUTCOME;

EID: 8444224241     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.04.011     Document Type: Article

References (21)

1. Lowenberg B. Managing therapy in older adult patients with acute myeloid leukemia. Semin. Hematol. 38:2001;10-16
2. Behringer B., Pitako J.A., Kunzmann R., Schmoor C., Behringer D., Mertelsmann R., et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Ann. Hematol. 82:2003;381-389
3. Rowe J.M. Treatment of acute myelogenous leukemia in older adults. Leukemia. 14:2000;480-487
4. Proceedings of the Symposium on Acute Leukemia Forum 95: Advances and Controversies in Induction Therapy and Treatment of Older Adults with AML. San Francisco, CA, USA; 10 November 1995. Leukemia 1996;10(Suppl)1:S1-48.
5. Sekeres M.A., Stone R.M. The challenge of acute myeloid leukemia in older patients. Curr. Opin. Oncol. 14:2002;24-30
6. McGavin J.K., Spencer C.M. Gemtuzumab ozogamicin. Drugs. 61:2001;1317-1322. discussion 1323-4
7. Ikemoto N., Kumar R.A., Ling T.T., Ellestad G.A., Danishefsky S.J., Patel D.J., et al. Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc. Natl. Acad. Sci. U.S.A. 92:1995;10506-10510
8. Sievers E.L., Appelbaum F.R., Spielberger R.T., Forman S.J., Flowers D., Smith F.O., et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 93:1999;3678-3684
9. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Lowenberg B., Dombret H., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19:2001;3244-3254
10. Bross P.F., Beitz J., Chen G., Chen X.H., Duffy E., Kieffer L., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7:2001;1490-1496
11. Giles F.J., Kantarjian H.M., Kornblau S.M., Thomas D.A., Garcia-Manero G., Waddelow T., et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 92:2001;406-413
12. Rajvanshi P., Shulman H.M., Sievers E.L., McDonald G.B. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 99:2002;2310-2314
13. Wadleigh M., Richardson P.G., Zahrieh D., Lee S.J., Cutler C., IIo V., et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 102:2003;1578-1582
14. Erba H., Stadtmauer E., Larson R., Sievers E.L., Estey E.H., Lowenberg B., et al. Final results of a multivariate logistic regression analysis to determine factors contributing to the risk of developing hepatic veno-occlusive disease following treatment with gemtuzumab ozogamicin. Blood. 100:2002;339a. abstract # 1313
15. DeAngelo D., Stone R., Durrant S., Delong L., Baccarani M., Schiffer C.A., et al. Gemtuzumab ozogamicin (Mylotarg) in combination with induction chemotherapy for the treatment of patients with de novo acute myeloid leukemia: two age-specific phase 2 trials. Blood. 102:2003;100a. abstract # 341
16. Nabhan C., Rundhaugen L., Riley M., Boehlke L., Jatoi M., Tallman M.S. Phase II trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older. Blood. 102:2003;618a. abstract # 2282
17. Gordon L.I. Gemtuzumab ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen. Bone Marrow Transplant. 28:2001;811-812
18. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8:1990;813-819
19. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials. 10:1989;1-10
20. Estey E.H., Thall P.F., Giles F.J., Wang X.M., Cortes J.E., Beran M., et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 99:2002;4343-4349
21. Lancet J.E., Rosenblatt J.D., Karp J.E. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Semin. Hematol. 39:2002;31-35